Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(62.5%)

Phase 1

2(25.0%)

Phase 4

1(12.5%)

8Total

N/A(5)

Phase 1(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03944408Not ApplicableUnknown

A Metal Bare Stent With 125 Iodine （125I）Seeds for the Treatment of Malignant Central Airway Stenosis

Role: collaborator

NCT03084809Phase 4Completed

Chemotherapy Combined With CIK Treating Colon Cancer

Role: lead

NCT02930993Phase 1Unknown

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

Role: lead

NCT02930967Phase 1Unknown

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

Role: lead

NCT02352012Not ApplicableUnknown

Interventional Treatment of Refractory Pneumothorax by Bronchoscope

Role: collaborator

NCT02277366Terminated

Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population

Role: collaborator

NCT02268162Not ApplicableUnknown

Diagnosis of Individuals With Pulmonary Nodules by Different Bronchoscopy Combination

Role: collaborator

NCT02299830Not ApplicableUnknown

Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture

Role: collaborator

NCT02287389Not ApplicableUnknown

Study of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture

Role: collaborator

All 9 trials loaded